🌟🧬💉 Bio SB and Precision Medicine: Conference on the Fundamentals of Immunohistochemistry in the Fight Against Cancer 🎗️🏥🔬
- Luis Fernando Heras Portillo
- Aug 25
- 3 min read
By Luis Fernando Heras Portillo
🔹 Introduction
Cancer 🎗️ remains one of the greatest challenges in modern medicine. In this context, immunohistochemistry (IHC)has revolutionized how tumors are diagnosed and how personalized treatments are designed.
To highlight its importance, Dr. Alfonso Heras Portillo, President and Director of Bio SB Inc., delivered the lecture “Fundamentals of Immunohistochemistry (IHC) for Cancer Diagnosis and Treatment Prediction” at Hospital San José – Center of Oncology Specialty.
The event brought together leading professionals from the medical and business fields, including:
👨💼 Jesús Espinoza Morales, General Manager of Bio SB México
👨⚕️ Dr. Danny Mena Cortes, nuclear medicine specialist.
👨⚕️ Dr. Luis Eduardo García Lafarga, President of the Association of Private Hospitals of the Northeast, Medical Manager of San José Hospital.
👨⚕️ Dr. Enrique Ávila Monteverde, Medical Director of Oncología San José, surgical oncologist.
👨⚕️ Dr. Alfonso Heras Portillo, President and Director of Bio SB.
👨💼 Luis Fernando Heras Portillo, Associate.
👨💼 Mr. Luis Fernando Heras Gastelum, Deputy Director of Bio SB Mexico.
🌍 From Sonora to the world: Bio SB is now present in 90 countries, bringing innovation in immunohistochemistry for cancer diagnosis 🎗️.
👨🔬 Dr. Alfonso Heras Portillo’s Trajectory
Born in Hermosillo, Sonora, Mexico, Dr. Heras Portillo is an international leader in biotechnology applied to oncology:
🎓 Veterinary Medicine from the National Autonomous University of Mexico (UNAM).
📚 Ph.D. in Biomedical Sciences from the University of California, Santa Barbara (UCSB).
🌐 Recognized speaker at international forums such as the United States and Canadian Academy of Pathology (USCAP) and the European Congress of Pathology.
Through Bio SB, he has spearheaded the development of:
Highly specific antibodies (IVD) 🧬.
Advanced detection systems 🔍 such as ImmunoDetector.
Automation platforms 🤖 that reduce diagnostic variability.
His leadership has positioned Bio SB as a global biotechnology company, with a presence in 90 countries and a growing influence in Mexico’s healthcare system.
🎤 Key Points from the Conference
In his presentation, Dr. Heras Portillo outlined Bio SB’s vision and the role of IHC in modern oncology:
1️⃣ Early Diagnosis and Personalized Medicine
Early detection saves lives. IHC identifies molecular markers in the early stages of cancer.
Each tumor has a unique “molecular fingerprint,” allowing IHC to personalize treatment and improve therapeutic effectiveness.
Medicine should shift from general protocols to tailored strategies for each patient.
2️⃣ Technological Integration in Oncology
Bio SB develops multiplexed antibodies that analyze multiple biomarkers in a single sample.
Digital pathology 📲 enables cloud storage and remote collaboration among specialists worldwide.
Artificial intelligence and machine learning 🤖 improve image interpretation, reducing diagnostic variability and enhancing accuracy.
3️⃣ Accessibility of Biotechnology in Mexico and Worldwide
Innovation must reach beyond elite labs. Bio SB is working to make advanced diagnostics accessible to regional hospitals and community centers.
In Mexico, infrastructure challenges remain, but training and affordable diagnostic kits are helping close the gap.
With presence in over 90 countries, Bio SB demonstrates Mexico’s capacity to compete in global biotechnology.
4️⃣ Multidisciplinary Collaboration Against Cancer
Fighting cancer requires multidisciplinary teams: oncologists, pathologists, surgeons, nuclear medicine specialists, and biotechnologists.
The conference at Hospital San José was an example of this collaboration, bridging science, medicine, and business.
Bio SB also partners with universities and research centers to train the next generation of specialists.
5️⃣ Commitment to Sustainable Innovation 🌱
The future of biotechnology must also be environmentally responsible.
Bio SB is already developing eco-friendly reagents and processes.
As Dr. Heras noted, the future of medicine depends not only on human health, but also on the health of the planet. 🌍
💬 Highlights
The meeting provided an opportunity to reflect on the importance of collaboration between physicians, researchers, and business leaders. Among the most relevant statements:
Dr. Enrique Ávila Monteverde highlighted the importance of having cutting-edge technologies to save lives in northern Mexico.
Dr. Danny Mena Cortes pointed out how the integration of nuclear medicine and immunohistochemistry can enhance treatment precision.
Bio SB México's commitment to medical training and strengthening the national healthcare system was reaffirmed.
🌍 Global Presence in 90 Countries
Bio SB has become a world leader in immunohistochemistry, with distribution in more than 90 countries. Its products are used in:
Hospitals 🏥
Clinical laboratories 🔬
Universities 🎓
Research centers 🧪
This international reach places Mexico as a global innovator in biotechnology.
🇲🇽 Growth Across Mexico
Beyond its global footprint, Bio SB continues to expand within Mexico:
Active participation in national oncology and pathology congresses.
Strategic partnerships with high-specialty hospitals, such as Hospital San José.
Creation of highly specialized jobs in biotechnology and diagnostics.
Promotion of continuous medical education through workshops and conferences.
This growth strengthens Mexico’s role as a regional leader in cancer diagnostics and precision medicine.
Comments